60～70岁患者主动脉机械瓣与生物瓣中期疗效对比

目的 对比分析60~70岁患者行主动脉瓣机械瓣置换与生物瓣置换术后生存率、术后瓣膜并发症情况及再次手术率的差异。 方法 回顾性分析2005年1月至2015年12月在解放军总医院第一医学中心心血管外科行主动脉瓣机械瓣置换的64例60~70岁患者与同年龄段的147例行主动脉瓣生物瓣置换的患者的病例资料。根据术前基线资料,利用倾向性评分匹配方法对患者分组。分组后比较两组患者瓣膜置换术后的生存率、瓣膜相关病死率、瓣膜相关并发症发生率及再次手术率的差异。 结果 倾向性评分匹配后,机械瓣组与生物瓣组术后6年,两组患者的生存率及瓣膜相关病死率无统计学差异(P=0.160,P=1.000)。机械瓣组术后并发症包括机械瓣非结构性功能异常1例(2.1%),栓塞1例(2.1%)、出血1例(2.1%),生物瓣组术后并发症包括瓣膜血栓1例(2.1%)、栓塞4例(8.2%)。总体的并发症发生率两组无统计学差异(P=0.321)。生物瓣组6年内再次手术1例(2.1%),机械瓣组未发生再次手术,组间比较无统计学差异(P=1.000)。 结论 我中心60至70岁年龄段患者行主动脉瓣机械瓣或生物瓣置换术后6年的生存率、瓣膜相关病死率、并发症发生率及再次手术率无明显差异。     

Comparison of outcome after valve replacement with a bioprosthesis versus a mechanical prosthesis: initial 5 year results of a randomized trial

The Veterans Administration Cooperative Study on Valvular Heart Disease was organized to compare survival and incidence of valve-related complications between patients receiving a bioprosthesis (the Hancock porcine heterograft) and a mechanical prosthesis (the Bj?rk-Shiley spherical disc valve). Five hundred seventy-five patients undergoing single aortic or mitral valve replacement were randomized at surgery to one of the two valve types. At an average follow-up of 5 years (range 3 to 8) there are no statistically significant differences in survival between patients with the two valve types in the aortic valve replacement group. There is a statistically nonsignificant trend toward improved survival in patients undergoing mitral valve replacement with a bioprosthesis compared with a mechanical prosthesis (5 year survival probability was 0.70 +/- 0.05 and 0.58 +/- 0.06, respectively). Fatal and nonfatal valve-related complications occurred significantly less frequently in patients with a bioprosthesis compared with a mechanical prosthesis for both mitral and aortic valve replacement. Five year complication-free probability was 0.67 +/- 0.05 and 0.45 +/- 0.06, respectively, for patients with mitral valve replacement and 0.63 +/- 0.04 and 0.53 +/- 0.04, respectively, for those with aortic valve replacement. The difference in overall complication rates was largely due to the increased number of clinically significant but nonfatal bleeding episodes in patients receiving a mechanical prosthesis. Adjustment for differences in baseline characteristics between patients receiving a mitral mechanical prosthesis and a mitral bioprosthesis reduced the statistical significance of the difference in both mortality and complications.     

Minimally invasive versus conventional aortic valve replacement: a prospective randomized trial

BACKGROUND AND AIM OF THE STUDY: A prospective randomized study was performed to compare conventional with minimally invasive aortic valve replacement (AVR). METHODS: Forty consecutive patients scheduled for elective aortic valve surgery were prospectively randomized either to the conventional group (group A, complete median sternotomy) or minimally invasive group (group B, partial upper sternotomy). Intraoperative and postoperative clinical data, and markers of myocardial and cerebral protection were determined. Neuropsychological tests were carried out to quantify psychological disorders. RESULTS: Operative time and cardiopulmonary bypass time were slightly longer in group B, but not significantly so. No significant inter-group differences were found for postoperative pain scores and respiratory function. Chest tube drainage was significantly less in group B (495 +/- 165 versus 240 +/- 69 ml, p = 0.008). Creatine kinase (CK), CK-MB and troponin T levels were similar in both groups. Neither S-100B protein nor neuron-specific enolase levels differed significantly between groups at all sampling times. There were no strokes in the entire cohort. None of the neuropsychological tests yielded significant inter-group differences between conventional and minimally invasive surgery. CONCLUSION: The safety and reliability of AVR via a partial upper sternotomy is reported. Minimally invasive AVR can be performed with only slightly longer operative times, good cosmetic results and significantly less blood loss. A limited surgical access affected neither the patients' neurological outcome nor the efficacy of myocardial protection.     

Transvenous-subcutaneous implantation of a cardioverter-defibrillator after bioprosthetic replacement of a tricuspid valve

The implantation of transvenous devices in patients who underwent tricuspid valve replacement represents problems, especially if an epicardial position is not available. The implantation of a "pace-sense" lead via the coronary sinus is a safe and feasible procedure. For experienced surgeons in implantation of biventricular devices, the implantation of leads via the coronary sinus is a routine procedure. Bipolar leads are essential for the correct sensing and pacing of the implantable cardioverter-defibrillator (ICD). In patients who underwent tricuspid valve replacement who have the indication of an ICD implantation postoperatively, the combination of a shock electrode placed in the superior vena cava, a subcutaneous array positioned on the left posterior close to the spine and an active can, placed subpectorally in the left infraclavicular region, is an alternative solution.     

Separation of a Beall Surgitool prosthesis disk 15 years after mitral valve replacement

The case of a 46-year-old woman who survived disc embolization of a Beall Surgitool prothesis for 10 days is described. The patient presented to another hospital 15 years after implantation of a mitral valve prothesis with acute severe heart failure refractory to medical therapy. Ten days later she was referred for cardiological investigation and a missing mitral valve disc was diagnosed by echocardiography and right heart catheterization. Immediate surgical valve replacement led to a good recovery. The embolized disc was later localized by ultrasound and abdominal CT and removed from the abdominal aorta.     

Endoscopic versus operative gastrostomy: final results of a prospective randomized trial

This study compared operative gastrostomy (OG) (by surgeons) with endoscopic gastrostomy (PEG) (by physicians) in a prospective randomized fashion to determine whether one technique was superior. PEG (Sachs-Vine) and OG (Stamm) were done using local anesthesia. Patients were assessed for complications, mortality, tube function, and cost. Groups were equally matched for indications and underlying disease. Fifty-seven had OG and 64 had attempted PEG. Complications occurred in 26% of OG patients and 9% died. Complications occurred in 25% of PEG patients and 12% died. Tube feeding was initiated in both groups within a mean of 29 (24 to 72) hours of the gastrostomy placement. OG cost $1675 and PEG $979 to perform. Twenty-one PEG patients required endoscopic tube change which raised their total cost to $1574. We conclude there is no difference between OG (using local anesthesia) and PEG with regard to morbidity, mortality, or tube function. The endoscopic technique does appear to have economic advantage.     

Comparative analysis of structural valve deterioration and long-term clinical outcomes after bovine pericardial versus porcine bioprosthetic mitral valve replacement

BackgroundThis study aimed to compare long-term outcomes, including durability, after bovine pericardial valve replacement with those after porcine mitral valve replacement (MVR).MethodsWe enrolled 309 patients who underwent MV replacement (mean age: 65.8±11.5 years; 68.9% females) with Carpentier-Edwards PERIMOUNT bovine pericardial valves (bovine MVR group, n=241) or Hancock II porcine bioprosthesis (porcine MVR group, n=68). The mean clinical and echocardiographic follow-up durations were 81.4±60.0 and 57.8±53.3 months, respectively. Structural valve deterioration (SVD) was defined as prosthetic mitral valve (MV) regurgitation or stenosis of greater than moderate degree combined with a motion limitation, tear, or perforation of prosthetic valve leaflet on follow-up echocardiography. Propensity score (PS)-adjusted multivariable analyses were performed.ResultsThirty-day mortality rate was 6.4% (20/309 patients). SVD occurred in 50 patients (33 and 17 patients in the bovine and porcine MV replacement groups, respectively). Cumulative incidences of SVD at 5, 10, and 15 years were 3.2%, 15.9%, and 32.4%, respectively, in the bovine MVR group and 1.9%, 15.3%, and 41.7%, respectively, in the porcine MVR group. Cumulative incidences of SVD in the two groups were not different in competing risk analysis (P=0.23). Other clinical outcomes including overall survival and cumulative incidences of cardiac death and MV-related events were not statistically significantly different between the groups in PS-adjusted multivariable analyses.ConclusionsLong-term clinical outcomes including SVD were not different between the bovine and porcine bioprosthesis MVR groups during average 7 years of clinical follow-up after MVR.     

Valvular replacement with the Bicarbon mechanical valve. Results after 7 years in 104 patients

OBJECTIVE: Study of the medium term results of aortic and mitral valve replacement with the Bicarbon' prosthesis. METHOD: From 1990 to 1996, 109 valves were implanted (70 in aortic position, 31 in mitral position and 4 double replacements). The average age was 61 years and 75% were male. According to the NYHA, 59% of patients were stage III or IV. The average pre-operative ejection fraction was 59.6%. There was re-intervention in 21.1% of patients and 35.3% had an associated procedure during the intervention. RESULTS: The average follow up was 5.4 +/- 1.98 years in 98 patients (that is 522 patient years). One patient died post-operatively and 19 died later. The overall survival at 7 years was 69.4 +/- 6.3%. Complications, expressed in patient years, were 1.15% for thrombo-embolic complications, 2.1% for haemorrhagic complications. 0.38% for endocarditis, 1.72% for non-infectious peri-prosthetic leaks, and 0.76% for re-interventions. At 7 years, the absence of thrombo-embolic, haemorrhagic, endocarditis, and re-intervention complications was 91.8 +/- 4.2%, 85.3 +/- 4.8%, 95.8 +/- 3.2%, 93.8 +/- 3.5% respectively. According to the NYHA, 95% of patients were in stage 1 or II (p < 0.001). CONCLUSION: Valvular replacement in the aortic or mitral position with the Bicarbon' valve is satisfactory as much in terms of survival as of clinical complications.     

Influence of pregnancy after bioprosthetic valve replacement in young women: a prospective five-year study

BACKGROUND AND AIMS OF THE STUDY: Prosthetic heart valve placement in young women does not normally prevent successful pregnancy, though either thrombosis in mechanical prostheses or degeneration in biological prostheses may cause risks for both mother and fetus. Although pericardial prostheses avoid the risks of anticoagulation therapy, it has been suggested that pregnancy accelerates structural degeneration in bioprostheses. The study aim was to assess the influence of pregnancy on five-year outcome after pericardial bioprosthesis replacement. METHODS: A total of 85 women was studied prospectively over five years from prosthesis implantation, using annual clinical and echocardiographic investigations. Women were allocated to two groups based on pregnancy occurring during follow up: 48 patients (56%; group A) became pregnant, and 37 (44%; group B) did not. RESULTS: At five-year follow up, the clinical events occurred in 29 patients (34.1%): 11 (22.9%) women in group A (mean (+/-SE) linearized rate 3.6+/-0.24%/patient-year (pt-yr)), and 18 (45.6%) in group B (linearized rate 8.6+/-0.30%/pt-yr). Probability of freedom from clinical events was higher (p = 0.0096) in group A (77.9+/-6.1 versus 51.3+/-8.2%). Structural bioprosthesis degeneration, thrombosis or infective endocarditis occurred in 13 patients (27.1%) in group A (linearized rate 2.75+/-0.20%/pt-yr) and 11 (29.7%) in group B (linearized rate 2.5+/-0.18%/pt-yr). Probability of structural bioprosthesis degeneration (e.g. stenosis, calcification or rupture) did not differ (p = 0.6440) between groups (85.4+/-5.1 versus 89.5+/-5.1%), even after age-adjusted analysis (p = 0.3112). CONCLUSION: Structural changes found at five years after bioprosthesis placement may be attributed to the natural course of the bioprosthesis, and independent of any occurrence of pregnancy.     

Functional incidental training: a randomized, controlled, crossover trial in Veterans Affairs nursing homes

OBJECTIVES: To test the effects of a rehabilitative intervention directed at continence, mobility, endurance, and strength (Functional Incidental Training (FIT)) in older patients in Department of Veterans Affairs (VA) nursing homes. DESIGN: Randomized, controlled, crossover trial. SETTING: Four VA nursing homes. PARTICIPANTS: All 528 patients in the nursing homes were screened; 178 were eligible, and 107 were randomized to an immediate intervention group (Group 1; n=52) and a delayed intervention group (Group 2; n=55). INTERVENTION: Trained research staff provided the FIT intervention, which included prompted voiding combined with individualized, functionally oriented endurance and strength-training exercises offered four times per day, 5 days per week, for 8 weeks. Group 1 received the intervention while Group 2 served as a control group; then Group 2 received the intervention while Group 1 crossed over to no intervention. A total of 64 subjects completed the intervention phase of the trial. MEASUREMENTS: Timed measures of walking or wheeling a wheelchair (mobility), sit-to-stand exercises, independence in locomotion and toileting as assessed using the Functional Independence Measure (FIM), one-repetition maximum weight for several measures of upper and lower body strength, frequency of urine and stool incontinence, and appropriate toileting ratios. RESULTS: There was a significant effect of the FIT intervention on virtually all measures of endurance, strength, and urinary incontinence but not on the FIM for locomotion or toileting. The effects of FIT were observed when Group 1 received the intervention and was compared with the control group and when Group 2 crossed over to the intervention. Group 1 deteriorated in all measures during the 8-week crossover period. Within-person comparisons also demonstrated significant effects on all measures in the 64 participants who completed the intervention; 43 (67%) of these participants were "responders" based on maintenance or improvement in at least one measure of endurance, strength, and urinary incontinence. No adverse events related to FIT occurred during the study period. CONCLUSION: FIT improves endurance, strength, and urinary incontinence in older patients residing in VA nursing homes. Translating these positive benefits achieved under research conditions into practice will be challenging because of the implications of the intervention for staff workload and thereby the costs of care.     

Successful double bioprosthetic valve replacement in a 64-year-old man with carcinoid syndrome and bipolar disorder: case report

The case is described of a 64-year-old man with bipolar disorder and severe carcinoid heart disease who required a double valve replacement. Multidisciplinary team involvement and extensive preoperative investigations resulted in a successful regimen which prevented reactivation of carcinoid syndrome and avoided the serious side effects of lantreotide and lithium therapy. In addition, two bioprosthetic valves were used, thereby avoiding the potential complications of anticoagulation in a patient with known hepatic metastases.     

Early postoperative anticoagulation after mechanical valve replacement: a Canadian survey

BACKGROUND AND AIM OF THE STUDY: The optimal approach to anticoagulation during the early postoperative period after mechanical valve replacement, by which early thromboembolism is prevented without bleeding complications, is not yet known. The study aim was to examine the practice patterns of Canadian cardiac surgeons with regard to early postoperative anticoagulation after mechanical valve implantation. METHODS: A questionnaire was sent to 100 Canadian cardiac surgeons in July 2004, and 57 responses were received. Data were collected regarding the approaches to early postoperative anticoagulation following uncomplicated isolated mechanical aortic valve replacement (AVR) and mitral valve replacement (MVR). RESULTS: Heparin was administered routinely after AVR and MVR by 63% and 68% of surgeons, respectively. This was most commonly initiated on postoperative day (POD) 1, and given either subcutaneously (AVR, 28%; MVR, 25%) or intravenously (AVR, 33%; MVR, 42%). Alternatively, low-molecular-weight heparin was used by 21% and 23% of surgeons after AVR and MVR, respectively. Oral warfarin was usually started on POD 1 (72% and 68%, respectively), with 40% prescribing an initial dose between 2.5 and 5.0 mg, and 51% administering between 5.1 and 7.5 mg. When heparin was not used, oral anticoagulation was more often administered earlier (AVR, p = 0.003; MVR, p = 0.006), but not at higher doses (AVR, p = 0.07; MVR, p = 0.2). Following surgery, aspirin was prescribed by 61% and 65% of surgeons after AVR and MVR, respectively. CONCLUSION: The study results highlighted a significant variability in the management of early postoperative anticoagulation after mechanical valve implantation. The clinical impact of these findings is unknown, and can only be assessed through a prospective trial.     

Low-dose oral anticoagulation in patients with mechanical heart valve prostheses: final report from the early self-management anticoagulation trial II.

AIMS: In mechanical heart valve recipients, low-dose international normalized ratio (INR) self-management of oral anticoagulants can reduce the risk of developing thrombo-embolic events and improve long-term survival compared with INR control by a general practitioner. Here, we present data on the safety of low-dose INR self-management. METHODS AND RESULTS: In a prospective, randomized multi-centre trial, 1346 patients with a target INR range of 2.5-4.5 and 1327 patients with a target INR range of 1.8-2.8 for aortic valve recipients and an INR range of 2.5-3.5 for mitral or double valve recipients were followed up for 24 months. The incidence of thrombo-embolic events that required hospital admission was 0.37 and 0.19% per patient year in the conventional and low-dose groups, respectively (P = 0.79). No thrombo-embolic events occurred in the subgroups of patients with mitral or double valve replacement. The incidence of bleeding events that required hospital admission was 1.52 and 1.42%, respectively (P = 0.69). In the majority of patients with bleeding events, INR values were < 3.0. Mortality rate did not differ between the study groups. CONCLUSION: Data demonstrate that low-dose INR self-management does not increase the risk of thrombo-embolic events compared with conventional dose INR self-management. Even in patients with low INR target range, the risk of bleeding events is still higher than the risk of thrombo-embolism.     

Natural course of left atrial thrombi after bioprosthetic mitral valve replacement in a patient with heparin-induced thrombocytopenia

Left atrial (LA) clots involving prosthetic mitral valves are unusual complications of heparin-induced thrombocytopenia (HIT), and little is known about their natural history. A 73-year-old woman underwent bioprosthetic mitral valve replacement, which was complicated by atrial fibrillation and LA thrombus due to HIT. She was treated medically and followed up for 18 months. The present case provides unique insights into the natural history of HIT-related LA thrombus involving a bioprosthetic valve. It highlights the importance of having a high index of suspicion for this condition and avoiding the use of warfarin early in the course of the condition.     

Outcome after aortic valve replacement: comparison of homografts with mechanical prostheses

BACKGROUND AND AIM OF THE STUDY: Aortic valve replacement (AVR) in younger patients is conventionally performed using a mechanical prosthesis (MP), although homograft (HG) implantation is an accepted alternative. This study compares, retrospectively, the follow up of these two dissimilar prostheses. METHODS: Since 1990, a total of 147 Sorin Bicarbon MPs and 285 HGs have been implanted at the authors' institution, and compared statistically for survival, reoperation rate and valve-dependent complications. Only patients aged <70 years were included in the study. RESULTS: The demographic parameters of both patient groups differed with regards to gender, age at the time of implantation, and duration of follow up. Survival was superior in the HG group (log-rank, p = 0.01). Sixteen of 42 late deaths in the MP group were valve-related due to cerebral infarction (n = 7), ventricular arrhythmias (n = 3), or ventricular failure (n = 6). Six of 24 deaths after HG implantation were valve-related (all prosthesis infections). The choice of valve type and patient age were independent risk factors in the multivariate analysis. Freedom from reoperation was superior after MP implantation (log rank, p = 0.007); in six MP patients the indications for redo surgery were prosthesis infection (n = 2) and paravalvular leak (n = 4). In 20 HG patients, redo surgery was required due to prosthesis infection (n = 12), stenotic degeneration (n = 2), regurgitation > grade II (n = 4), or paravalvular leak (n = 2). Age at the time of implantation and valve type were independent risk factors. Thromboembolic complications were mainly seen in MP patients (log rank, p <0.001): there were five ischemic infarctions and 11 transient ischemic attacks (TIAs) compared to three TIAs among HG patients. Cerebral bleeding was found in only 18 cases after MP implantation, and in no cases after HG implantation. In the multivariate analysis, the type of prosthesis was an independent risk factor. CONCLUSION: As expected, these data confirm a longer time period without need for reoperation after MP implantation, but demonstrate a significantly higher survival and fewer complications after AVR with HG.